TxCell
Les Cardoulines HT1, Allée de la Nertière,
Sophia Antipolis
Valbonne
06560
France
Tel: 33-0-497-218-300
Fax: 33-0-493-641-580
Website: http://www.txcell.com/
Email: contact@txcell.com
116 articles about TxCell
-
TxCell: financial information for the 3rd quarter of 2018
11/7/2018
TxCell SA today reports its financial information for the 3rd quarter of 2018.
-
TxCell terminates its OCABSA financing program following closing of the acquisition by Sangamo of a majority stake in TxCell
10/1/2018
TxCell SA today announces that the actions provided for by the agreement entered into between TxCell and Yorkville in July 2018
-
TxCell terminates its OCABSA financing program following closing of the acquisition by Sangamo of a majority stake in TxCell
10/1/2018
TxCell SA today announces that the actions provided for by the agreement entered into between TxCell and Yorkville in July 2018 (the “Agreement”), to further improve the terms of its OCABSA financing program in the context of the closing of the acquisition by Sangamo Therapeutics, Inc. of a majority stake of TxCell, have now been completed as planned (see TxCell’s press release dated July 23, 2018). The OCABSA financing program is therefore terminated.
-
Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares
10/1/2018
Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy.
-
TxCell announces first-half 2018 financial results and update on the proposed acquisition by Sangamo Therapeutics, Inc.
9/20/2018
TxCell SA today announces financial results for the first half of 2018 and provides an update on the proposed acquisition by Sangamo Therapeutics, Inc.
-
Sangamo Therapeutics to Acquire TxCell
7/23/2018
The Proposed Acquisition Would Combine Sangamo's Ex Vivo Gene Editing Capabilities and TxCell's Treg Expertise and Would Position Sangamo as a Leader in CAR-Treg Development
-
TxCell Shares Surge After Sangamo Therapeutics Announces it Will Acquire the French Company
7/23/2018
Shares of France’s TxCell S.A. have skyrocketed about 150 percent this morning after Sangamo Therapeutics announced it was acquiring a majority stake in the company for €72 million (about $82 million) in a cash deal. -
TxCell Announces 4th Quarter 2017 Financials and Participation at Upcoming Scientific Conferences
1/24/2018
TxCell today reports its fourth quarter 2017 financials and provides an update on its financing.
-
TxCell Announces its Financial Calendar for 2018
1/8/2018
TxCell, a developer of cellular immunotherapies based on regulatory T cells for inflammation, autoimmunity and transplantation, today announces its financial calendar for 2018.
-
TxCell Completes CAR-Treg Manufacturing Process Development and Provides Update to CMO Selection
12/19/2017
The process will be transferred to a CMO before the start of a first-in-man clinical trial.
-
TxCell: Financial Information for the 3rd Quarter of 2017
10/20/2017
xCell today reports its revenues for the third quarter of 2017 and its cash position as of September 30, 2017.
-
TxCell Participation At Final COST AFACTT Meeting
10/6/2017
-
TxCell To Present Two Posters At ESGCT 2017
10/2/2017
-
TxCell Presents New Proof-Of-Concept Transplantation Results With Proprietary Second-Generation CAR-Tregs
9/27/2017
-
TxCell First-Half 2017 Financial Results And Strategy Update
9/21/2017
-
TxCell To Hold Conference Call On Friday, September 22, 2017 Following The Publication Of Its First-Half 2017 Financial Results
9/19/2017
-
TxCell: Presentation Of New Transplantation CAR-Treg Data At ESOT 2017
9/14/2017
-
TxCell To Present New Data On CAR-Treg Construct Optimization At CAR-TCR Summit
9/5/2017
-
TxCell: Financial Information For The 2nd Quarter Of 2017
7/27/2017
-
TxCell Appoints Lentigen Technology, Inc. To Manufacture The Lentiviral Vector For Its First CAR-Treg Program In Transplant Rejection
6/20/2017